# 2025-08960: FDA Seeks Input on a Rare Deficiency and Chemotherapy

2025-08960, Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs; Establishment of a Public Docket; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-20, effective 2025-06-20 (as of 2026-10-21).

- Canonical: https://policyrisk.com/federal-register/2025-08960
- As of: 2026-10-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08960
- Title: Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs; Establishment of a Public Docket; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 21483
- Published: 2025-05-20
- Effective: 2025-06-20
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-21

## In one line

FDA Seeks Input on a Rare Deficiency and Chemotherapy

## Summary

The FDA is opening a public comment period to learn more about a condition called DPD deficiency, which can affect how people react to certain chemotherapy drugs like fluorouracil and capecitabine. This effort aims to gather info to keep patients safe and improve treatment. Anyone interested has until June 20, 2025, to share their thoughts—no costs or immediate changes yet, just gathering input!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of fluorouracil and capecitabine (both fluoropyrimidine chemotherapy drugs). The purposes of the docket establishment are to foster Agency transparency and to solicit input on the currently available information on DPD deficiency and the use of fluorouracil and capecitabine.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-14967](https://policyrisk.com/federal-register/2025-14967): Requirements for Additional Traceability Records for Certain Foods: Compliance Date Extension, 2025-08-07

## Sources
- [2025-08960 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/20/2025-08960/dihydropyrimidine-dehydrogenase-deficiency-and-the-use-of-fluoropyrimidine-chemotherapy-drugs)
- [2025-08960 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-20/pdf/2025-08960.pdf)

## Related
- [Previous: 2025-08959, Notice of Annual Factors for Determining Administrative Fees for the Section 8…](https://policyrisk.com/federal-register/2025-08959)
- [Next: 2025-08961, Agency Information Collection Activity: Application for Dependency and Indemnit…](https://policyrisk.com/federal-register/2025-08961)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08960 (as of 2026-10-21).
